CITIZEN PETITION
Universal Nonprescription Access for
FDA-Approved Human Drugs
Sole Exclusion: Federally Scheduled Controlled Substances
Including an evidence-based rebuttal to
safety, access, economic, and implementation objections
Submitted under 21 C.F.R. Section 10.30
|
Policy request
|
Make every FDA-approved human
drug available without a prescription or other FDA-created purchase gate
unless it contains an active ingredient in federal Schedule I, II, III, IV,
or V.
|
|
Important limitation
|
This petition does not claim that
every noncontrolled drug is safe for unsupervised use, or that available
evidence proves most prescription drugs are safer than most OTC drugs. It
argues that legal availability is not a rank order of danger and that risk
analysis must include the harms of undertreatment, delayed care, and cost
barriers.
|
Dockets
Management Staff (HFA-305)
Food
and Drug Administration
5630
Fishers Lane, Room 1061
Rockville,
Maryland 20852
Submitted: June 25, 2026
Citizen
Petition
Date: June 25, 2026
The undersigned submits this petition under sections 503(b),
505, 505-1, and 701(a) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
Sections 353(b), 355, 355-1, and 371(a), and 21 C.F.R. Sections 10.30 and
310.200. Petitioner requests universal nonprescription access for approved
human drugs that do not contain federally scheduled controlled substances;
removal of every other FDA-created purchase condition; preservation of
non-gating safety authorities; and a legislative recommendation for any part of
the requested endpoint that current law does not authorize. [1]-[5][10]-[13]
|
Petitioner
|
Contact information
|
|
David Behar, MD
|
700 Hagys Ford Road, Penn Valley,
PA 19072
dbehar322@gmail.com
(610) 389-1716
|
|
Scope of request
|
All therapeutic fields,
indications, strengths, dosage forms, routes, and populations are included.
The single requested exclusion is a drug containing a federally scheduled
controlled substance. Ordinary manufacturing, labeling, truthful-promotion,
recall, and postmarket authority remain in force but may not be used as a
retail purchase gate for included drugs.
|
|
Current-law notice
|
This filing requests a change in
policy and, where necessary, federal law. It does not state that existing
prescription drugs may currently be sold without a prescription, and it is
not medical advice.
|
Contents
- A. Action Requested
- B. Statement of Grounds
- C. Environmental Impact
- D. Economic Impact
- E. Certification
- References and Citation Attachments
- Appendix A - Universal Inclusion Scope and Sole
Exclusion
- Appendix B - Model Coverage Continuity and Neutrality
Rule
- Appendix C - Non-Gating Consumer Information and
Support Standard
- Appendix D - Model Federal Statutory Amendment
- Appendix E - Objections, Warnings, Unfavorable
Evidence, and Rebuttals
- Appendix F - Access, Competition, Price, Utilization,
and Profit Framework
A.
Action Requested
Petitioner requests a universal nonprescription-access
policy for every human drug approved under section 505 of the FD&C Act,
with one categorical exclusion: a drug containing an active ingredient listed
in Schedule I through V under the Controlled Substances Act. The requested
endpoint is lawful retail purchase without a prescriber, prior diagnosis,
laboratory test, questionnaire, pharmacist authorization, enrollment,
certification, package limit, duration limit, or other FDA-created condition.
[2]-[7][10]-[13]
1. Adopt
universal nonprescription status. Every approved human drug that does not
contain an Excluded Controlled Substance should be exempt from federal
prescription-dispensing requirements and lawfully purchasable without a
prescription.
2. Use one
sole categorical exclusion. The only excluded class should be a drug
containing an active ingredient listed in Schedule I, II, III, IV, or V under
21 U.S.C. Section 812 or 21 C.F.R. Part 1308, as amended. [10]-[12]
3. Remove all
other FDA purchase gates. For included drugs, purchase should not depend on
a prescription, practitioner order, pharmacist authorization, prior diagnosis,
prior treatment, laboratory result, screening questionnaire, ACNU, REMS
enrollment, age or sex verification, indication or strength limit, route or
dosage-form limit, package size, quantity, duration, or refill rule.
4. Include
every therapeutic field and product type. The rule should apply without
categorical exception to psychiatric, neurologic, cardiovascular, endocrine,
metabolic, oncology, immunologic, transplant, anti-infective, reproductive,
respiratory, gastrointestinal, renal, urologic, dermatologic, ophthalmic, otic,
emergency, anesthetic, and hospital-use drugs, and to every approved strength,
dosage form, route, and population.
5. Initiate
Commissioner-led class proceedings. FDA should create a master docket and
coordinated class dockets, identify all approved noncontrolled products, and
initiate section 310.200 proceedings rather than waiting exclusively for
sponsor petitions. [3][6]
6. Amend 21
C.F.R. Section 310.200. FDA should adopt the proposed universal exemption
text below to the fullest extent permitted by current law and identify the
statutory amendment needed for the remainder. [2][3][5]
7. Remove
conflicting FDA restrictions. FDA should revise approval conditions,
guidance, labeling limitations, and REMS elements that operate as conditions of
purchase for included drugs. Where current law prevents removal, FDA should
transmit Appendix D. [4][7][13]
8. Use
information rather than gatekeeping. FDA may require accurate labeling,
warnings, directions, contraindications, packaging, manufacturing controls,
safety communications, recalls, and adverse-event reporting, but those measures
should not deny or delay purchase. [7]-[9][14]
9. Keep AI,
testing, pharmacists, and clinicians optional. A consumer may voluntarily
use an AI tool, laboratory test, pharmacist, clinician, telehealth service, or
other support. Completion or approval by any service should never be a
condition of purchase.
10. Apply the
policy equally to brands and generics. Therapeutically equivalent products
should transition on coordinated dates, with common consumer information where
scientifically appropriate, so no sponsor receives an access monopoly.
11. Prevent a
coverage cliff. FDA should publish a coverage-impact statement and formally
refer Appendix B to HHS, CMS, the Departments of Labor and the Treasury,
States, and Congress so reclassification does not terminate coverage solely
because a product becomes nonprescription. [15][16][30]
12. Use
postmarket surveillance without restoring a prescription gate. FDA should
monitor adverse events, medication errors, overdose, interactions, delayed
diagnosis, pregnancy outcomes, antimicrobial resistance, product quality,
disparities, coverage loss, and shortages, and respond through non-gating
authorities. [14][29]
13. Publish a
comparative-risk and access report. FDA should compare the harms of use
with the harms of nonuse, undertreatment, delayed treatment, current OTC
substitution, and access friction. The report should not presume that OTC
status means low risk or that prescription status means greater danger.
[18]-[24]
14. Create a
transparent price, utilization, safety, and supply dashboard. For each
transitioned product or class, FDA and HHS should track cash price,
out-of-pocket cost, coverage, manufacturer entry, utilization, treatment
initiation, persistence, adverse events, poison-center signals, shortages, and
disparities at 6, 12, 24, and 36 months. [22]-[30]
15. Transmit a
legislative proposal. Within 180 days, FDA should send HHS and Congress the
model language in Appendix D and a list of statutory provisions that prevent
full implementation.
Proposed
regulatory text
Current section 310.200(b) permits Commissioner-initiated
prescription-exemption proceedings, but section 503(b) may not permit the full
universal endpoint by regulation alone. FDA should adopt the following text to
the fullest lawful extent and transmit Appendix D for the balance. [2][3][5]
(b) Universal prescription exemption. Except as provided in
paragraph (c), every human drug approved under section 505 of the act is exempt
from prescription-dispensing requirements and may be sold to a consumer without
a prescription.
(c) Sole exclusion for federally controlled substances.
Paragraph (b) does not apply to a drug containing an active ingredient listed
in Schedule I, II, III, IV, or V under section 202 of the Controlled Substances
Act or part 1308 of this title. The exclusion changes automatically when the
federal schedule changes.
(d) No other purchase condition. For a drug covered by
paragraph (b), FDA shall not require, as a condition of retail purchase, a
prescription, practitioner order, pharmacist authorization, prior diagnosis,
prior use, laboratory test, questionnaire, additional condition for
nonprescription use, REMS enrollment or certification, age or sex verification,
limitation by indication, strength, route, dosage form, package size, quantity,
duration, refill, or any comparable condition.
(e) Information and postmarket authority preserved. Nothing
in this section limits FDA authority to require accurate labeling, warnings,
directions, contraindications, packaging, manufacturing controls, adverse-event
reporting, postmarket studies, safety communications, recalls, or application
changes, provided those measures do not operate as a condition of retail
purchase for a drug covered by paragraph (b).
(f) Equal therapeutic scope. A drug shall not be excluded
from paragraph (b) because of therapeutic field, toxicity, narrow therapeutic
index, need for monitoring, pregnancy risk, route, dosage form,
professional-use history, REMS status, antimicrobial status, psychiatric use,
oncology use, or hospital-use history.
(g) Implementation. FDA shall publish a master list of
included and excluded products, coordinate transition dates for therapeutically
equivalent products, revise conflicting approval conditions and guidance,
publish safety and economic monitoring results, and identify statutory barriers
for referral to Congress.
B.
Statement of Grounds
1.
Current law provides the prescription standard, an exemption mechanism, and a
limit on FDA's present authority.
Section 503(b) presently requires prescription dispensing
when a drug is not safe for use except under practitioner supervision or when
an approved application limits it to professional supervision. Section 310.200
preserves prescription status until FDA grants an exemption and allows the
Commissioner to initiate the exemption proceeding. [2][3]
This petition asks FDA to use existing authority at the
broadest lawful scale, build a public record, and state candidly where section
503(b) prevents the requested endpoint. It also asks FDA to recommend
legislation rather than treating an asserted lack of authority as a reason not
to evaluate universal access. [1][5]
2.
The Controlled Substances Act supplies a distinct and administrable sole
exclusion.
The Controlled Substances Act establishes Schedules I
through V, current regulations identify scheduled substances, and federal law
separately imposes prescription, medical-purpose, recordkeeping, and diversion
controls. [10]-[12]
Under the requested bright-line rule, an approved drug
enters or leaves the exclusion when its federal schedule changes. The petition
acknowledges that scheduling does not capture every serious non-addiction risk
and every misuse signal; it nevertheless supplies a defined federal boundary
and a separate process for newly supported scheduling action.
3.
Access barriers and undertreatment are safety outcomes, not merely
conveniences.
A prescription requirement imposes time, travel,
appointment, administrative, and financial costs before a consumer can obtain
the product. FDA's ACNU regulatory impact analysis estimated a primary
reduction in consumer access costs of $33.62 per purchase, with a range of $0
to $67.23, for a hypothetical prescription-to-nonprescription transition. FDA
did not project national totals and emphasized uncertainty. [25]
National data show that access failures remain substantial.
In 2024, 7.3% of adults failed to obtain needed medical care because of cost.
In 2022, adults also reported delayed or forgone care because appointments were
unavailable, they were too busy, offices were inaccessible when open, providers
did not accept their insurance, or travel took too long. [22][23]
Mental-health undertreatment illustrates the stakes. In
2024, 29.5 million adults with any mental illness did not receive mental-health
treatment; 6.1 million of those adults perceived an unmet need, and cost was
among the most commonly reported reasons. These data do not prove that
medication access alone resolves the treatment gap, but they establish that
non-treatment and access friction must be included in the safety comparison.
[24]
4.
OTC and prescription status are legal access categories, not a rank ordering of
danger.
FDA warns that excessive acetaminophen can cause severe
liver damage, transplantation, and death; high-dose diphenhydramine can cause
serious heart problems, seizures, coma, or death; and aspirin-containing
antacid products can cause gastrointestinal bleeding that may require
transfusion. These products are available without a prescription. [18]-[20]
Those examples do not prove that all or most prescription
drugs are safer than all or most OTC drugs. No comprehensive dataset in this
record supports that sweeping comparison. They do rebut the premise that OTC
status is synonymous with low hazard or that prescription status necessarily
identifies greater toxicity. The proper analysis is comparative and includes
dose, use, population, untreated disease, substitution, and barriers to care.
Prescription status also does not eliminate harm. Shehab and
colleagues estimated approximately four emergency-department visits for
outpatient adverse drug events per 1,000 individuals annually in 2013-2014;
27.3% of estimated visits involved hospitalization. Commonly implicated classes
included anticoagulants, diabetes agents, and opioid analgesics. [21]
5.
Overdose and poisoning warnings are real, but they do not by themselves justify
a universal permission gate.
Intentional overdose, accidental pediatric ingestion,
duplicate ingredients, and dosing errors are representative unfavorable
information. The petition does not ask FDA to hide or minimize them. It asks
whether a prescription prerequisite is the least harmful and most effective
response for every noncontrolled product.
Many overdose-prevention tools do not require advance
permission: clear maximum-dose labeling, standardized ingredient names,
child-resistant and unit-dose packaging, poison-control information, emergency
instructions, public education, adverse-event signal detection, label changes,
recalls, and scheduling referral when warranted. [14][18]-[21]
6.
Misdiagnosis and delayed care must be compared with delay created by the
current access model.
A consumer may self-treat the wrong condition, overlook a
red flag, or postpone needed care. The opposite error also matters: a person
may remain untreated because the appointment, cost, travel, scheduling, or
administrative burden is too high. [22][23]
FDA should require clear limits-of-use and
emergency-referral information and make professional support easy to obtain.
The petition objects to turning those supports into prerequisites that recreate
the barrier they are meant to solve.
7.
Monitoring, interactions, pregnancy risks, and administration risks support
information and services, but not necessarily denial of purchase.
Some included drugs require titration, sterile technique,
laboratory interpretation, interaction review, therapeutic drug monitoring,
pregnancy counseling, or rapid management of adverse effects. These concerns
are serious and are not fully captured by the controlled-substance exclusion.
Petitioner asks FDA to distinguish a recommended clinical
practice from a legal condition of ownership or purchase. Strong warnings,
optional testing, private decision support, caregiver information, professional
administration services, and postmarket action can remain. For any step current
law requires as an element to assure safe use, Appendix D requests amendment.
[13][14]
8.
Psychiatric access requires balancing medication risk against the risks of
untreated illness and interrupted care.
Warnings about activation, suicidality, sedation,
withdrawal, relapse, and interaction must be prominent. At the same time,
national data document a large mental-health treatment gap and frequent cost
concerns. [24]
The petition therefore rejects a one-sided analysis in which
the only counted harm is use of the medicine. FDA should also count
non-initiation, interruption, relapse, crisis care, and adverse consequences of
untreated disease, while preserving crisis information, optional counseling,
and active surveillance.
9.
Antimicrobial resistance is a major unfavorable externality and requires a
national non-gating stewardship system.
CDC reports that bacterial antimicrobial-resistant
hospital-onset infections caused by selected pathogens increased during the
pandemic and that most remained above pre-pandemic rates in 2022. Unnecessary
or incorrect antimicrobial use can harm both the user and the public. [29]
Petitioner nevertheless requests nonprescription purchase
and proposes resistance surveillance, voluntary rapid testing, stewardship
labeling, public reporting, restrictions on false or misleading promotion, and
rapid public-health action. Residual resistance risk is acknowledged and should
be measured rather than omitted.
10.
Optional AI, laboratory testing, pharmacists, and clinicians can expand support
without becoming exclusionary infrastructure.
Digital tools and professional services can identify
interactions, organize symptoms, improve comprehension, provide monitoring, and
refer emergencies. They can also produce false reassurance, false denial,
privacy loss, algorithmic bias, data lock-in, and unequal access.
Appendix C permits prominent and convenient voluntary
support but prohibits a purchase condition based on an account, identity check,
score, answer, test, third-party payment, or data disclosure. Loss of a digital
service must never interrupt product availability.
11.
Coverage continuity is essential to prevent legal access from becoming
financial inaccessibility.
Medicaid and Medicare rules do not treat all nonprescription
products as covered prescription drugs. An OTC transition can therefore
eliminate the prescriber gate while imposing a cash-price barrier. [15][16]
Evidence on cost sharing reinforces the concern. A
systematic review and meta-analysis found increased odds of nonadherence in
publicly insured populations exposed to prescription copayments. Appendix B
requests permanent coverage of at least one therapeutic equivalent,
reimbursement without a prescription-only visit, transition protection, and
monitoring of abandonment. [30]
12.
Competition can reduce prices, increase use, and create large commercial
opportunities, but the outcome is not automatic.
FDA found that generic prices were lower relative to
pre-entry brand prices as the number of competitors increased: the median AMP
reduction was 39% with one generic producer, 54% with two, 79% with four, and
more than 95% with six or more. FDA cautioned that these measures do not fully
represent consumer prices and that very low prices can coincide with shortages.
[26]
FDA separately estimated $18.6 billion in first-year net
savings from 2023 generic approvals under its model. Such estimates support the
value of entry but do not guarantee the retail price of any universal
transition. [27]
Lower effective prices and lower access costs generally
increase use, but sensitivity differs by drug and class. Einav, Finkelstein,
and Polyakova found substantial heterogeneity in drug-specific and
therapeutic-class demand elasticities. [28]
The commercial mechanism is straightforward: revenue equals
price times quantity, and operating contribution can be represented as (price
minus unit cost) times quantity minus fixed cost. A lower unit price can
produce higher total revenue and potentially very large profit if volume
expands enough and supply remains efficient. Petitioner expects this incentive
to attract manufacturers and expand use, but does not claim that profit is
guaranteed, that every class is elastic, or that profit is an FDA approval
criterion. [25]-[28]
13.
Market concentration, coverage changes, liability, and shortages can defeat the
expected price-and-volume mechanism.
Prices may remain high if entry is limited, distribution is
concentrated, payer coverage ends, liability or relabeling costs rise, or
supply is fragile. Lower manufacturer prices may not reach consumers. Rapid
utilization growth can also create shortages.
The requested implementation therefore coordinates brands
and generics, prohibits an access monopoly, preserves coverage, publishes cash
and out-of-pocket prices, tracks manufacturer entry and shortages, and asks
competition authorities to review exclusionary conduct. [15][16][25]-[30]
14.
A universal policy requires legislative candor and a transparent record.
Current section 503(b) expressly considers toxicity, harmful
potential, method of use, and collateral measures. It may not permit FDA to
exempt every noncontrolled drug without product-specific findings. Existing
REMS provisions may also conflict with unrestricted purchase. [2][13]
The petition therefore asks FDA to act to the fullest lawful
extent, open a public record, identify products and barriers, and transmit
Appendix D. It does not represent that the universal endpoint is already
authorized.
15.
The petition includes warnings and unfavorable information rather than treating
them as reasons to suppress the proposal.
Appendix E collects the principal medical, legal, economic,
equity, antimicrobial, supply, and implementation objections and states
residual risks. The petition's policy judgment is that non-gating information,
voluntary services, coverage, and postmarket action are preferable to a legal
purchase veto for noncontrolled drugs. FDA and Congress may disagree; the
requested docket should make that disagreement evidence-based and transparent.
C.
Environmental Impact
Petitioner claims categorical exclusion under 21 C.F.R.
Section 25.30(h) for the requested initiation of rulemaking, guidance, public
dockets, data collection, interagency referral, and legislative recommendation
because those procedural actions do not themselves approve a particular drug,
change a particular product's intended use, or authorize a particular increase
in production. To petitioner's knowledge, no extraordinary circumstances exist
for those procedural actions. [17]
If FDA treats a final universal exemption, a
product-specific approval change, or another substantive implementation step as
requiring an environmental assessment or a different categorical-exclusion
analysis, petitioner requests that FDA sever or sequence that action and obtain
the product-specific information required at that stage. This filing does not
purport to supply product-specific environmental fate, manufacturing-volume,
disposal, or ecological data. [17]
D.
Economic Impact
Economic impact information will be submitted if requested
under 21 C.F.R. Section 10.30(b). The central economic theory is that removing
prescription acquisition costs and coordinating generic competition will reduce
effective consumer cost, increase treatment initiation and continuation, expand
quantity demanded, and create large revenue opportunities. FDA's own ACNU
analysis recognizes meaningful access costs per purchase, and FDA's
generic-competition work associates more competitors with lower manufacturer
and pharmacy-acquisition price measures. [1][25]-[27]
The petition does not present price reductions, utilization
increases, or manufacturer profit as certainties. Drug-specific demand is
heterogeneous; retail and out-of-pocket prices depend on insurance, rebates,
distribution, and market structure; and low prices can undermine supply
resilience. [26][28]
For clarity, the proposed mechanism is: (1) remove a time
and permission cost; (2) preserve coverage; (3) coordinate brand and generic
transition; (4) lower cash and out-of-pocket price through entry and
competition; (5) increase initiation, adherence, and persistence where demand
responds; and (6) allow aggregate revenue and potentially profit to rise when
added volume more than offsets lower unit margin and fixed costs. Appendix F
states the assumptions, countervailing forces, and required measures.
Economic evaluation should report results separately for
Medicare, Medicaid, employer coverage, Marketplace coverage, uninsured
consumers, rural communities, people with disabilities,
limited-English-proficiency populations, and consumers who do not use digital
tools. It should include adverse events, emergency care, antimicrobial
resistance, product liability, relabeling costs, manufacturing investment,
shortage risk, and FDA, HHS, and DEA administrative costs. [15][16][22]-[30]
The agency should not count a manufacturer's expected profit
as a public-health benefit by itself. Profit is relevant as an incentive for
entry, production, distribution, lower prices, innovation, and promotion, and
it can be large when market expansion is substantial. The public-interest
measures are affordable access, appropriate use, health outcomes, equity,
safety, and reliable supply.
E.
Certification
The undersigned certifies, that, to the best knowledge and
belief of the undersigned, this petition includes all information and views on
which the petition relies, and that it includes representative data and
information known to the petitioner which are unfavorable to the petition.
David Behar, MD
700 Hagys Ford Road
Penn Valley, PA 19072
Telephone: (610) 389-1716
Email: dbehar322@gmail.com
Date: June 25, 2026
References
and Citation Attachments
Each numbered citation below corresponds to a PDF in the
references folder and in the compiled Reference Source Volume. The filing
includes complete PDFs for every cited peer-reviewed journal article.
Government webpages that did not provide a stable agency PDF are included as
clearly labeled filing-generated webpage captures; the source URL and content
date appear on each capture.
1. 21 C.F.R. Section 10.30, "Citizen petition".
Attachment: Ref_01_21_CFR_10_30_Citizen_Petition.pdf. Petition format and
certification.
2. 21 U.S.C. Section 353(b), prescription dispensing and
exemption standards. Attachment: Ref_02_21_USC_353_Prescription_Standard.pdf.
Current prescription-supervision standard.
3. 21 C.F.R. Section 310.200, prescription-exemption
procedure. Attachment: Ref_03_21_CFR_310_200_Prescription_Exemption.pdf.
Commissioner- or petitioner-initiated exemption procedure.
4. 21 U.S.C. Section 355, new-drug approval provisions.
Attachment: Ref_04_21_USC_355_New_Drugs.pdf. Approval authority.
5. 21 U.S.C. Section 371, regulations and hearings.
Attachment: Ref_05_21_USC_371_Regulations_and_Hearings.pdf. General rulemaking
authority.
6. FDA, Increasing Access to Nonprescription Drugs; Public
Meeting; Request for Comments, 91 Fed. Reg. 20170. Attachment:
Ref_06_FDA_Increasing_Access_Public_Meeting_2026.pdf. Current access initiative
and public docket.
7. Current OTC Drug Facts and ACNU regulations, 21 C.F.R.
Sections 201.66, 201.67, 201.130, and 314.56. Attachment:
Ref_07_Current_OTC_and_ACNU_Regulations.pdf. Nonprescription labeling and
additional-condition framework.
8. FDA Guidance: Label Comprehension Studies for
Nonprescription Drug Products. Attachment:
Ref_08_FDA_Label_Comprehension_Guidance.pdf. Consumer understanding studies.
9. FDA Guidance: Self-Selection Studies for Nonprescription
Drug Products. Attachment: Ref_09_FDA_Self_Selection_Studies_Guidance.pdf.
Consumer self-selection studies.
10. 21 U.S.C. Section 812, establishment of
controlled-substance schedules. Attachment:
Ref_10_21_USC_812_Controlled_Substance_Schedules.pdf. Schedules I-V.
11. 21 U.S.C. Section 829, prescriptions for controlled
substances. Attachment:
Ref_11_21_USC_829_Controlled_Substance_Prescriptions.pdf. Prescription rules
for scheduled drugs.
12. 21 C.F.R. Part 1308, federal controlled-substance
schedules. Attachment:
Ref_12_21_CFR_Part_1308_Controlled_Substance_Schedules.pdf. Current regulatory
schedules.
13. 21 U.S.C. Section 355-1, risk evaluation and mitigation
strategies. Attachment: Ref_13_21_USC_355_1_REMS.pdf. REMS and elements to
assure safe use.
14. 21 C.F.R. Section 314.80, postmarketing
adverse-drug-experience reporting. Attachment:
Ref_14_21_CFR_314_80_Postmarketing_Reporting.pdf. Postmarket reporting
authority.
15. 42 U.S.C. Section 1396r-8, Medicaid outpatient-drug
provisions. Attachment: Ref_15_42_USC_1396r_8_Medicaid_OTC.pdf. Medicaid
treatment of nonprescription drugs.
16. CMS, Over-the-Counter Drug Reference File Frequently
Asked Questions. Attachment: Ref_16_CMS_OTC_Reference_File_FAQ.pdf. Coverage
and rebate administration.
17. 21 C.F.R. Part 25 environmental assessment and
categorical-exclusion provisions. Attachment:
Ref_17_Current_Environmental_Impact_Regulations.pdf. Environmental statement.
18. FDA, Don't Overuse Acetaminophen. Attachment:
Ref_18_FDA_Acetaminophen_Consumer_Update_Webpage_Capture.pdf. OTC overdose,
liver failure, transplant, and death warning.
19. FDA, High-dose diphenhydramine warning. Attachment:
Ref_19_FDA_Diphenhydramine_High_Dose_Warning_Webpage_Capture.pdf. OTC heart
problems, seizures, coma, and death warning.
20. FDA, Aspirin-containing antacid bleeding warning.
Attachment: Ref_20_FDA_Aspirin_Antacid_Bleeding_Warning_Webpage_Capture.pdf.
OTC gastrointestinal bleeding warning.
21. Shehab et al., U.S. Emergency Department Visits for
Outpatient Adverse Drug Events, JAMA 316:2115-2125 (2016). Attachment:
Ref_21_Shehab_JAMA_Outpatient_Adverse_Drug_Events.pdf. Burden and drug classes
involved in outpatient adverse drug events.
22. NCHS, Early Release of Selected Estimates Based on the
2024 National Health Interview Survey. Attachment:
Ref_22_CDC_2024_NHIS_Early_Release_Access_to_Care.pdf. Cost-related unmet
medical care.
23. NCHS, Sociodemographic Differences in Nonfinancial
Access Barriers to Health Care Among Adults: United States, 2022. Attachment:
Ref_23_CDC_Nonfinancial_Access_Barriers_2022.pdf. Appointment, time, travel,
insurance acceptance, and other access barriers.
24. SAMHSA, 2024 NSDUH mental-health treatment-gap extract.
Attachment:
Ref_24_SAMHSA_2024_NSDUH_Mental_Health_Treatment_Gap_Official_Extract.pdf.
Mental-health undertreatment and perceived cost barrier.
25. FDA, Final Regulatory Impact Analysis for
Nonprescription Drug Product With an ACNU. Attachment:
Ref_25_FDA_ACNU_Final_Regulatory_Impact_Analysis.pdf. Estimated consumer
access-cost reduction and economic uncertainties.
26. FDA, Generic Competition and Drug Prices: New Evidence
Linking Greater Generic Competition and Lower Generic Drug Prices. Attachment:
Ref_26_FDA_Generic_Competition_and_Drug_Prices.pdf. Generic entry and lower
manufacturer/wholesale price measures, with limitations.
27. FDA, Estimated Savings From Generic Drug Approvals in
2023. Attachment: Ref_27_FDA_Generic_Approvals_Savings_2023.pdf. Estimated
savings associated with generic approvals.
28. Einav, Finkelstein, and Polyakova, Drug-Specific Price
Elasticities and Cost Sharing in Medicare Part D, AEJ: Economic Policy
10(3):122-153 (2018). Attachment:
Ref_28_Einav_Finkelstein_Polyakova_Drug_Price_Elasticities.pdf. Demand responds
to out-of-pocket price, with substantial heterogeneity.
29. CDC, Antimicrobial Resistance Threats in the United
States, 2021-2022. Attachment:
Ref_29_CDC_Antimicrobial_Resistance_Threats_2021_2022.pdf.
Antimicrobial-resistance burden and stewardship warning.
30. Sinnott et al., Effect of Copayments on Medication
Adherence, PLOS ONE 8(5):e64914 (2013). Attachment:
Ref_30_Sinnott_PLOS_Copayments_and_Medication_Adherence.pdf. Copayments and
nonadherence in publicly insured populations.
APPENDIX
A
Universal Inclusion Scope and Sole Exclusion
This Appendix is incorporated into the petition. Every human
drug approved under section 505 is requested to be available for
nonprescription purchase unless it contains an active ingredient listed in
Schedule I through V under the Controlled Substances Act. No other negative
list, risk tier, continuation-only pathway, test, diagnosis, package limit,
strength limit, indication limit, or route limit is requested. [2]-[4][10]-[12]
1.
Operative definitions
- Included drug: any human drug with an effective
section 505 approval that does not contain an Excluded Controlled Substance.
- Excluded Controlled Substance: an active ingredient
listed in federal Schedule I, II, III, IV, or V under 21 U.S.C. Section 812 or
21 C.F.R. Part 1308, as amended.
- Purchase gate: any prescription, practitioner order,
pharmacist approval, test, questionnaire, prior diagnosis, prior treatment,
enrollment, certification, identity or age verification, indication or strength
restriction, route restriction, package or quantity limit, duration limit,
refill rule, ACNU, REMS condition, or comparable prerequisite imposed under FDA
authority as a condition of retail purchase.
- Non-gating safety measure: labeling, warnings,
directions, contraindications, packaging, manufacturing controls, adverse-event
reporting, safety communications, recalls, or postmarket studies that do not
prevent or delay purchase.
2.
Universal therapeutic inclusion
|
Therapeutic field
|
Representative included scope
|
Requested access
|
|
Primary care and internal
medicine
|
Pain, fever, allergy,
respiratory, gastrointestinal, renal, hepatic, hematologic, infectious, and
multisystem drugs
|
Unrestricted nonprescription
purchase unless federally scheduled
|
|
Psychiatry and neurology
|
Antidepressants, antipsychotics,
mood stabilizers, noncontrolled ADHD drugs, anticonvulsants, migraine,
dementia, Parkinson disease, and sleep drugs
|
Unrestricted nonprescription
purchase unless federally scheduled
|
|
Cardiovascular and coagulation
|
Antihypertensives,
antiarrhythmics, anticoagulants, antiplatelet drugs, lipid drugs,
heart-failure drugs, and pulmonary-vascular drugs
|
Unrestricted nonprescription
purchase unless federally scheduled
|
|
Endocrine and metabolic
|
Insulin and other diabetes drugs,
thyroid drugs, adrenal drugs, osteoporosis drugs, vitamins, minerals, and
metabolic-disease therapies
|
Unrestricted nonprescription
purchase unless federally scheduled
|
|
Oncology, immunology, and
transplant
|
Cytotoxic drugs, targeted
therapies, immunotherapies, immunosuppressants, and transplant drugs approved
under section 505
|
Unrestricted nonprescription
purchase unless federally scheduled
|
|
Anti-infective
|
Systemic and local antibacterial,
antiviral, antifungal, antiparasitic, and antimycobacterial drugs
|
Unrestricted nonprescription
purchase unless federally scheduled
|
|
Reproductive and sexual health
|
Contraception, fertility,
pregnancy-related, menopause, erectile-dysfunction, gynecologic, and urologic
drugs
|
Unrestricted nonprescription
purchase unless federally scheduled
|
|
Emergency, anesthetic, and
hospital-use
|
Emergency drugs, anesthetics,
vasopressors, inotropes, neuromuscular blockers, contrast agents, and
procedure-associated drugs
|
Unrestricted nonprescription
purchase unless federally scheduled
|
|
Dermatologic, ophthalmic, otic,
and local therapy
|
Topical, ocular, otic, nasal,
inhaled, vaginal, rectal, transdermal, and implantable drugs
|
Unrestricted nonprescription
purchase unless federally scheduled
|
3.
All strengths, dosage forms, routes, and populations
- All approved strengths and concentrations are
included.
- All approved dosage forms and routes are included,
including oral, topical, transdermal, inhaled, nasal, ophthalmic, otic,
vaginal, rectal, injectable, infused, implanted, and device-combination
presentations.
- All approved indications and populations are
included. Labeling may describe approved use, contraindications, and warnings
but should not be a purchase condition.
- Initiation, titration, continuation, refill, rescue,
and maintenance use receive the same nonprescription status.
- Brand and therapeutically equivalent generic products
transition together.
4.
Sole excluded category
|
Controlled category
|
Products remaining outside the requested policy
|
|
Controlled opioids
|
Schedule II-V opioid analgesics
and other scheduled opioid products
|
|
Controlled stimulants
|
Amphetamine, methylphenidate, and
other scheduled stimulants
|
|
Benzodiazepines and controlled
sedative-hypnotics
|
Scheduled anxiolytic, sedative,
hypnotic, and related products
|
|
Barbiturates and other controlled
depressants
|
Scheduled barbiturate and
depressant products
|
|
Controlled anabolic steroids and
testosterone
|
Products listed in federal
controlled-substance schedules
|
|
Other Schedule I-V substances
|
Any current or future active
ingredient in 21 U.S.C. Section 812 or 21 C.F.R. Part 1308
|
A product removed from all federal schedules would enter the
included category without a separate FDA negative-list proceeding. A newly
scheduled product would enter the exclusion on the effective date of
scheduling. [10]-[12]
APPENDIX
B
Model Rx-to-OTC Coverage Continuity and Neutrality Rule
1. Purpose. Prevent
nonprescription reclassification from causing loss of affordable access,
treatment interruption, or a visit required solely for reimbursement.
2. Covered
reclassified drug. Any drug or therapeutic equivalent that becomes
nonprescription under the requested policy.
3. Coverage
continuity. A plan that covered a prescription version immediately before
reclassification may not terminate coverage solely because the product is
nonprescription. The plan shall cover at least one FDA-approved therapeutic
equivalent at cost sharing no less favorable than the pre-switch preferred
option, subject only to clinically neutral formulary management.
4. Universal
therapeutic neutrality. The rule applies equally to psychiatric, oncology,
anti-infective, reproductive, metabolic, emergency, and all other included
therapeutic areas.
5. No
reimbursement-only prescription or visit. A plan may not require an office
visit or prescription whose sole purpose is reimbursement when federal law
permits nonprescription purchase. Plans should accept a pharmacy claim, NDC,
itemized receipt, standing order, or another reasonable proof of purchase.
6. Medicaid
transition. CMS should issue model State-plan and rebate guidance, identify
lawful pathways under 42 U.S.C. Section 1396r-8, and recommend statutory change
where a prescription condition would cause a coverage cliff. [15]
7. Medicare
transition. HHS should propose legislation or other lawful authority to
maintain coverage for a product that moves from covered prescription status to
nonprescription status. [16]
8. Notice and
transition. Plans shall provide clear advance notice, at least a 90-day
transition supply or equivalent access, an exception process, and continuity
during a timely appeal.
9. Permissible
neutral management. A payer may use preferred products, generic
substitution, fraud controls, and ordinary claims administration that do not
penalize a product solely because it is nonprescription.
10. Data and
audit. HHS and States should report coverage retention, abandonment,
out-of-pocket spending, utilization, emergency care, treatment continuity, and
disparate effects.
11. Duration. Coverage
continuity should be permanent for at least one clinically appropriate
equivalent, not merely a brief transition benefit.
|
Jurisdiction note
|
FDA can document and refer
coverage consequences but cannot, through drug-approval authority alone, bind
every public or private payer. This model is directed to HHS, CMS, the
Departments of Labor and the Treasury, States, and Congress. [15][16]
|
APPENDIX
C
Non-Gating Consumer Information and Support Standard
This Appendix preserves consumer information and voluntary
support while implementing the no-restriction rule. None of the following may
be required before purchase, used to deny purchase, or conditioned on payment
to or data sharing with a third-party service. [7]-[9]
1. Drug Facts
and approved information. Clear approved uses, directions,
contraindications, warnings, interactions, pregnancy information, overdose
information, storage, and emergency instructions in accessible formats.
2. Optional
pharmacist or clinician consultation. Retailers may make consultation or
referral available, but the consumer may decline without losing access.
3. Optional AI
and digital tools. A consumer may use an interaction checker, symptom
organizer, educational chatbot, dose reminder, or other tool. No score, answer,
identity check, account, or algorithmic approval may be required.
4. Optional
laboratory testing. A consumer may obtain baseline or monitoring tests
voluntarily. A result, proof of testing, standing order, or laboratory account
may not be required.
5. No
mandatory health-data collection. Purchase should not require disclosure of
diagnosis, medication history, pregnancy status, laboratory data, identity,
insurance, or other health information beyond separate law governing an
ordinary retail transaction.
6. Emergency
and poison information. Products should prominently identify emergency
symptoms, poison-control resources, overdose response, and the limits of
self-treatment.
7. Multiple
formats. Information should be available on the package and optionally by
paper insert, telephone, accessible website, audio, video, and translated
materials. Loss of a digital service must not interrupt access.
8. Postmarket
learning. Sponsors and FDA should analyze adverse events, medication
errors, overdose, interactions, delayed diagnosis, product misuse, resistance,
and disparities and update information promptly. [14][29]
9. No
conversion into a gate. FDA, a sponsor, retailer, payer, platform,
laboratory, pharmacist, or clinician should not convert an informational or
support service into a prerequisite for retail purchase.
APPENDIX
D
Model Federal Statutory Amendment
The following model is requested if FDA concludes that
current law does not permit full implementation. It is proposed legislative
language, not a statement of current law.
SECTION
1. UNIVERSAL NONPRESCRIPTION STATUS FOR NONCONTROLLED APPROVED HUMAN DRUGS.
(a) Amendment to section 503(b). Section 503(b)(1) of the
Federal Food, Drug, and Cosmetic Act is amended to provide that, except for a
drug containing a controlled substance listed in Schedule I, II, III, IV, or V
under section 202 of the Controlled Substances Act, a human drug with an
effective approval under section 505 shall not be limited to dispensing upon a
prescription.
(b) Sole exclusion. The Secretary may not establish an
additional categorical exclusion from nonprescription status for a drug covered
by subsection (a). A change in federal scheduling shall automatically change
the drug's status under subsection (a).
(c) No condition of purchase under the FD&C Act. For a
drug covered by subsection (a), the Secretary may not require under the
FD&C Act, as a condition of retail purchase, a prescription, practitioner
order, pharmacist authorization, prior diagnosis, prior use, laboratory test,
questionnaire, ACNU, REMS enrollment or certification, age or sex verification,
limitation by indication, strength, route, dosage form, package size, quantity,
duration, refill, or a comparable condition.
(d) Safety authorities preserved. The Secretary may require
accurate labeling, warnings, directions, contraindications, packaging,
manufacturing controls, adverse-event reporting, postmarket studies, safety
communications, recalls, and application changes, provided those measures do
not operate as a condition of retail purchase.
(e) Conforming amendment to section 505-1. Section 505-1 is
amended so that an element to assure safe use may not operate as a condition of
retail purchase for a drug covered by subsection (a). Medication Guides,
communication plans, packaging, postmarket studies, and non-gating risk
information may continue.
(f) Coverage recommendation. The Secretary shall submit
proposed conforming amendments to Medicare, Medicaid, and other federal health
programs to prevent loss of coverage solely because a drug becomes
nonprescription.
(g) Competition and coordinated transition. The Secretary
shall coordinate transition dates for therapeutically equivalent products,
avoid conferring exclusive nonprescription access on one sponsor, and report
manufacturer entry, prices, coverage, utilization, safety, and shortages.
(h) Effective date and transition. The amendments take
effect 24 months after enactment. FDA shall publish the list of excluded
scheduled products and coordinate relabeling and transition dates for included
products.
(i) Rule of construction. Nothing in this section changes
the Controlled Substances Act or authorizes distribution or dispensing of a
federally scheduled substance contrary to that Act. Separate statutes
administered by another federal agency remain in effect unless Congress
expressly amends them.
APPENDIX
E
Objections, Warnings, Unfavorable Evidence, and Rebuttals
This Appendix is incorporated into the certification. It
states material arguments against the requested policy, the petitioner's
response, and residual safeguards. A rebuttal does not erase the stated risk;
it explains why petitioner believes a purchase gate is not the preferred
response.
|
Objection or warning
|
Petitioner's rebuttal
|
Residual safeguard / limitation
|
|
OTC
conversion will cause overdose and poisoning.
|
The warning
is serious. The relevant comparison, however, is not risk versus zero risk.
Widely available OTC products already can cause fatal liver injury, seizures,
coma, and major bleeding. Availability status is not an ordinal toxicity
ranking. For a switch candidate, FDA should compare incremental access risk
with harms of untreated disease, delayed treatment, substitution, and current
access friction. [18]-[21]
|
Prominent
overdose instructions, child-resistant packaging, unit-dose options,
poison-control information, rapid label updates, surveillance, and recall
authority; no pre-purchase gate.
|
|
The
petition improperly claims all OTC drugs are more dangerous than most
prescription drugs.
|
The
petition makes no universal numerical claim. The evidence supports a narrower
and important point: some common OTC drugs carry severe or fatal risks, and
many noncontrolled prescription drugs may have lower absolute risk in
particular uses. Therefore, the OTC/Rx boundary cannot be defended as a
simple rank ordering of danger. Comparative product-level data remain
necessary. [18]-[21]
|
FDA should
publish a transparent comparative-risk framework and state uncertainty rather
than presume either category is uniformly safer.
|
|
Consumers
cannot diagnose themselves and may delay needed care.
|
Misdiagnosis
and delay occur under every access model, including when people cannot obtain
appointments. In 2022, adults reported appointment, time, travel, and
insurance-acceptance barriers; in 2024, 7.3% of adults failed to obtain
needed medical care because of cost. Removing a prescription gate can reduce
one source of delay, while labels can identify red flags and the limits of
self-treatment. [22][23]
|
Clear
stop-use/referral warnings, optional triage tools and professional
consultation, and postmarket monitoring of delayed diagnosis.
|
|
Physician
supervision prevents adverse drug events.
|
Professional
care can add value, but prescription status does not eliminate adverse
events. A national study estimated about four emergency-department visits for
outpatient adverse drug events per 1,000 individuals annually, and more than
one quarter resulted in hospitalization. The question is whether mandatory
permission adds enough net benefit to justify the access cost for each
product and use. [21]
|
Voluntary
clinical care, medication review, electronic interaction tools,
pharmacovigilance, and targeted safety communications.
|
|
Drug
interactions and polypharmacy make unrestricted access unsafe.
|
Interactions
are real for both OTC and prescription products. Mandatory prescribing is an
imperfect proxy for complete medication reconciliation, especially across
fragmented systems. Universal access should be paired with standardized
interaction warnings and optional private interaction checking, not a legal
purchase veto.
|
Prominent
contraindications, standardized ingredient names, voluntary
pharmacist/clinician review, and nonmandatory digital checks.
|
|
Narrow-therapeutic-index
drugs require laboratory or therapeutic monitoring.
|
Monitoring
may improve outcomes, but the petition distinguishes a recommended clinical
practice from a legal purchase condition. A consumer should be able to obtain
a drug without proving a test, while receiving unmistakable information about
why monitoring is recommended and what symptoms require urgent care.
|
Optional
low-cost testing, standing access to results, strong labeling, and
class-specific surveillance; FDA may change warnings or indications without
restoring a purchase gate.
|
|
Pregnancy,
fetal toxicity, and reproductive risks require screening.
|
These risks
are substantial and must be disclosed. Mandatory pregnancy testing or sex
verification can also create delay, privacy burdens, and inequitable denial.
The petition requests information, confidential voluntary testing, and urgent
referral pathways rather than compulsory proof before purchase.
|
Boxed and
Drug Facts warnings, optional tests, emergency contact information, pregnancy
registries, and rapid safety action.
|
|
Psychiatric
medicines could increase self-harm, activation, withdrawal, or inappropriate
use.
|
Psychiatric
illness is also widely undertreated. In 2024, 29.5 million adults with any
mental illness did not receive mental-health treatment; among those reporting
unmet need, cost was a common reason. The access benefit does not erase
suicide, activation, or withdrawal risks, but those risks should be weighed
against non-treatment and interrupted treatment rather than treated as
one-sided. [24]
|
Crisis
warnings, small initial packages offered voluntarily, refill continuity,
optional counseling, adverse-event surveillance, and immediate emergency
guidance.
|
|
Antimicrobials
will be overused and accelerate resistance.
|
Antimicrobial
resistance is a major public-health externality, and the petition does not
minimize it. The petition nonetheless rejects a purchase gate and instead
asks for strong stewardship information, diagnostic access, resistance
surveillance, dispensing data analysis, and rapid label changes. CDC found
resistant hospital-onset infections remained elevated in 2022. [29]
|
National
resistance dashboard, voluntary rapid testing, stewardship messages, limits
on promotion, and public-health response; residual externality acknowledged.
|
|
REMS drugs
and professional-use drugs cannot be made nonprescription safely.
|
Some
current REMS elements and administration methods are designed around
professional control. The petition asks FDA to separate purchase from
administration and to retain non-gating information, training, packaging,
postmarket studies, and facility standards imposed under other lawful
authorities. Current section 505-1 may require legislation for full
implementation. [13]
|
Legislative
amendment, product-quality controls, optional trained administration, and
immediate enforcement for unsafe promotion or manufacturing.
|
|
Children,
older adults, and cognitively impaired consumers are especially vulnerable.
|
Vulnerability
argues for accessible information, caregiver tools, child-resistant
packaging, and coverage - not automatically for a permission system that can
itself deny or delay care. The net effect may differ by population and must
be measured.
|
Age-appropriate
warnings, caregiver materials, accessible formats, poison prevention, and
stratified safety reporting.
|
|
Noncontrolled
drugs can still be misused, diverted, or addictive.
|
Controlled-substance
scheduling is not a perfect predictor of misuse potential. That is
unfavorable to the petition and is expressly acknowledged. The requested
bright line uses the existing federal scheduling process; FDA and DEA may
refer newly supported scheduling actions through that system. [10]-[12]
|
Misuse
surveillance, scheduling referral when statutory criteria are met,
anti-counterfeit controls, and truthful risk communication.
|
|
Removing
gates will increase counterfeit and unsafe online purchasing.
|
A legal
domestic channel can reduce incentives to use illicit sellers, but it cannot
eliminate counterfeits. The policy should preserve FDA registration,
manufacturing, labeling, track-and-trace, import, and enforcement authority.
|
Verified
supply chains, public authentication tools, enforcement, recalls, and
warnings about unlawful sellers.
|
|
Insurance
will stop covering products after an OTC switch.
|
This is a
major risk. A legal access reform that creates a cash-price barrier could
worsen inequity and reduce adherence. The petition therefore requests
permanent coverage continuity for at least one therapeutic equivalent and no
reimbursement-only prescription visit. [15][16][30]
|
Appendix B
coverage rule, claims pathways without a prescription, transition protection,
and reporting of abandonment and out-of-pocket spending.
|
|
Market
forces may not lower prices.
|
Competition
often lowers manufacturer and wholesale price measures, but not
automatically. FDA found larger generic price reductions with more
competitors, while expressly warning that those measures do not fully capture
consumer prices and that very low prices may coincide with shortages. [26]
|
Coordinated
multi-manufacturer transition, generic substitution, transparent cash prices,
anti-competitive enforcement referrals, and shortage monitoring.
|
|
Lower
prices may not materially increase treatment use.
|
Demand for
medicines is generally price responsive, but elasticities differ
substantially by drug and class. Copayment evidence also links cost sharing
with lower adherence. The petition therefore predicts an average access
effect, not a uniform response for every drug or person. [28][30]
|
Measure
utilization, initiation, persistence, adherence, and unmet need by product
and population; revise implementation when expected access gains fail to
occur.
|
|
The
petition promises manufacturers huge profits.
|
It does
not. Lower unit prices can coexist with higher total revenue and potentially
large profits when the increase in volume is sufficient, but profit depends
on unit margin, fixed cost, competition, payer behavior, liability, and
supply. FDA is not asked to guarantee profits, and profit is not the legal
approval standard. [25]-[28]
|
Publish
price, entry, volume, shortage, and where lawful aggregate revenue
indicators; prevent exclusive switch advantages and coordinate generics.
|
|
A universal
policy is overbroad and not supported by product-specific evidence.
|
This is the
strongest legal and evidentiary objection. Current section 503(b) is product-
and supervision-focused. Petitioner asks FDA to use existing authority to the
fullest extent, create a transparent record, and send Congress the model
amendment needed for the universal endpoint. [2][3][5]
|
Phased
administrative work, explicit statutory referral, public docket, and no claim
that current law already authorizes every requested step.
|
APPENDIX
F
Access, Competition, Price, Utilization, and Profit
Framework
This Appendix translates the petition's economic claims into
testable propositions. It does not promise a particular retail price,
utilization response, revenue level, or profit outcome.
1.
Proposed causal chain
|
Policy step
|
Expected mechanism
|
Evidence / limitation
|
|
Remove the permission and
appointment gate
|
Reduce time, travel, scheduling,
copay, and administrative costs before acquisition
|
FDA ACNU analysis estimates a
primary $33.62 reduction in access cost per purchase in its modeled setting.
[25]
|
|
Preserve insurance coverage
|
Prevent legal access from
becoming a cash-price barrier
|
Medicaid and Medicare rules
require coordinated coverage action; cost sharing can reduce adherence.
[15][16][30]
|
|
Coordinate multiple brand/generic
entrants
|
Increase price competition and
avoid a single-sponsor access monopoly
|
FDA observed greater generic
competition associated with lower manufacturer/wholesale price measures.
[26][27]
|
|
Lower effective patient price
|
Increase initiation, refill,
adherence, and persistence where demand responds
|
Drug and class elasticities are
heterogeneous but generally negative; copayments are associated with
nonadherence. [28][30]
|
|
Increase quantity and continuity
|
Reduce undertreatment and
treatment interruption for responsive conditions
|
National surveys document cost
and nonfinancial access barriers and mental-health treatment gaps. [22]-[24]
|
|
Expand market volume
|
Allow total revenue and
potentially profit to rise despite lower unit price
|
Outcome depends on volume
response, unit cost, fixed cost, competition, coverage, liability, and
supply; not guaranteed. [25]-[28]
|
2.
Basic commercial arithmetic
Revenue = P x Q. Operating contribution can be represented
as (P - c) x Q - F, where P is net unit price, Q is quantity, c is variable
unit cost, and F is fixed cost. A lower P can produce greater revenue and
profit when Q rises sufficiently and unit cost and fixed costs remain
controlled. Conversely, intense competition, weak demand response, coverage
loss, liability, or shortages can reduce or eliminate profit.
3.
Why the petition expects lower prices and higher use
Removing acquisition friction lowers the full price of
obtaining treatment even if the package price is unchanged. Coordinated generic
entry can lower manufacturer and acquisition price measures. Lower
out-of-pocket cost tends to increase utilization or adherence, although the
size of the response varies. [25][26][28][30]
4.
Why large profits are possible but not assured
A transition can open a much larger self-pay and retail
market, eliminate some prescriber-acquisition friction, and expand volume.
Efficient producers may earn very large aggregate profits if the market
expansion outweighs lower margins. That commercial opportunity can motivate
investment and distribution. It is a hypothesis to be tested, not a promised
result, a reason to tolerate monopoly, or a substitute for FDA's public-health
standards.
5.
Implementation levers
- Coordinate transition dates for therapeutically
equivalent brands and generics.
- Do not confer an exclusive OTC or nonprescription
position on one sponsor when equivalent products can transition.
- Preserve coverage for at least one equivalent and
permit claims without a prescription-only visit.
- Publish cash prices and typical out-of-pocket prices
in comparable units.
- Monitor manufacturer entry, exit, production
capacity, quality events, and shortages.
- Refer exclusionary conduct, collusion, or
anticompetitive distribution practices to the appropriate competition
authority.
- Prohibit false or misleading claims that
nonprescription status means the product is harmless.
6.
Required dashboard
|
Domain
|
Measures
|
|
Access
|
Time to acquisition; travel;
failed attempts; availability by geography; optional-service uptake
|
|
Affordability
|
List, cash, acquisition, and
out-of-pocket price; coverage retention; claim rejection; abandonment
|
|
Use
|
New starts; total units;
persistence; refill gaps; discontinuation; indication mix where lawful
|
|
Undertreatment
|
Condition-specific untreated or
undertreated rates; self-reported unmet need; delay to therapy
|
|
Safety
|
Adverse events; ED visits;
hospitalization; fatality; medication error; intentional and accidental
overdose
|
|
Public-health externalities
|
Antimicrobial resistance;
diversion; counterfeit events; product disposal and environmental signals
|
|
Competition and supply
|
Number of manufacturers;
concentration; entry/exit; quality failures; shortages; back orders
|
|
Commercial outcomes
|
Where lawful, aggregate sales
volume, revenue indicators, and investment; no confidential-data mandate
beyond authority
|
|
Equity
|
All metrics stratified by
insurance, income, age, disability, race/ethnicity where lawful, rurality,
language, and digital access
|
7.
Review triggers
- A statistically credible increase in severe adverse
outcomes should trigger immediate investigation, labeling, packaging, recall,
manufacturing, promotion, or scheduling action, not an automatic unexamined
return to a prescription gate.
- A coverage decline or sharp out-of-pocket increase
should trigger payer and legislative intervention under Appendix B.
- A shortage or concentration signal should trigger
supply and competition review.
- Failure to reduce undertreatment should trigger
examination of price, coverage, information, and distribution barriers rather
than an assumption that legal availability alone was sufficient.
- All public reports should state uncertainty,
comparison groups, confounding, and whether effects differ by product or
population.
